Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have evidence of KRAS G12C, G12D, G12V, G12A, G12S, or G13D mutation in tumor tissue or circulating tumor DNA
Histological or cytologically proven diagnosis of a locally advanced, unresectable, and/or metastatic solid tumor cancer
Have measurable disease per RECIST 1.1
Have an ECOG performance status of ≤1
Must not be pregnant and/or planning to breastfeed during the trial or within 180 days of the last dose of trial intervention
Must be able to swallow tablets
Participants with asymptomatic or treated CNS disease may be eligible
You may not be if
Have known active CNS metastases and/or carcinomatous meningitis
Have any unresolved toxicities from prior therapy greater than NCI CTCAE Version 5.0 Grade 1 at the time of starting trial treatment, except for alopecia, hearing loss, peripheral neuropathy and ongoing endocrinopathies controlled on appropriate replacement therapy
Have significant cardiovascular disease defined as unstable angina or acute coronary syndrome, history of myocardial infarction, known left ventricular ejection fraction or heart failure, uncontrolled or symptomatic arrhythmias.
Have known active hepatitis B virus (HBV), hepatitis C virus (HCV) or untreated HIV infection
Have other active malignancy unless in remission with life expectancy greater than 2 years.
Have active uncontrolled systemic bacterial, viral, fungal, or parasitic infection
Have history of non-infectious pneumonitis/interstitial lung disease that received steroids or has current clinically significant pneumonitis/interstitial lung disease
